Europese lancering UVLrx™ op 14e Aesthetic & Anti-Aging Medicine World Congress
MONTE CARLO, Monaco–(BUSINESS WIRE)– UVLrx Therapeutics™ kondigt – na een succesvol Noord-Amerikaans debuut bij de American Academy of Anti-Aging Medicine (A4M) in Las Vegas – met blijdschap aan dat het zijn intraveneuze lichttherapiesysteem UVL1500 in Europa lanceert. Dit gebeurt op het veertiende Aesthetic & Anti-Aging Medicine World Congress (AMWC), dat van 31 maart tot 2 april plaatsvindt. De conferentie, die onder wetenschappelijk toezicht van de World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM) staat, trekt meer dan tienduizend medici en onderzoekers uit meer dan 120 landen, die allemaal geïnteresseerd zijn in de rol van preventie binnen esthetische therapieën en anti-ouderdomsbehandelingen. UVLrx Therapeutics™ belicht op het congres de bewezen voordelen van de golflengtes van licht die het behandelsysteem UVLrx gebruikt ter vermindering van ontstekingen. Dit is momenteel een belangrijk punt binnen de gehele branche, die een waarde van 300 miljard dollar heeft.
UVLrx™ European Launch: Targeting 14th Annual Aesthetic& Anti-Aging Medicine World Congress
MONTE CARLO, Monaco–(BUSINESS WIRE)– After a successful North American debut last month at the American Academy of Anti-Aging Medicine (A4M) in Las Vegas, UVLrx Therapeutics™ is pleased to announce the official European launch of its intravenous light therapy treatment system, the model UVL1500, at this year’s 14 th Aesthetic & Anti-Aging Medicine World Congress (AMWC) from March 31 st to April 2 nd. Under the scientific supervision of the World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM), the conference will attract over 10,000 physicians and researchers from more than 120 countries who are interested in the role of prevention in global aesthetic and anti-aging management. At the Congress, UVLrx Therapeutics™ will highlight the clinically proven benefits of light wavelengths utilized by its UVLrx™ Treatment System* for reducing inflammation, a key issue facing the entire $300 billion global industry today.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160120006185/en/
The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body. (Photo: Business Wire)
“Inflammation is a common side effect of all aesthetic procedures, whether they be facial laser treatments, injections or surgery,” said Michael Harter, CEO and president of UVLrx. “By immediately reducing inflammation caused by an aesthetic procedure, our technology will minimize pain and accelerate healing, which in turn will lead to better results and a more satisfied post-op patient.”
“Beyond aesthetic procedures, chronic inflammation can occur due to pathogens in the bloodstream and just everyday stress,” commented Rowland Hanson, chairman of UVLrx. “Left untreated, chronic inflammation accelerates the aging process and has been linked to heart disease, cancer and Alzheimer’s disease. This is why UVLrx is an essential adjunct therapy for physicians practicing both aesthetic and anti-aging medicine.”
In addition to its exhibitor booth at the Congress, UVLrx has secured an adjacent private salon for physician and distributor on-site demonstrations of its CE-marked UVLrx Station™ Model UVL1500. Moreover, UVLrx Chief Science Officer, Ryan Maloney, has been asked to speak at a special session at noon on Friday, April 1 st, about the efficacy of ultraviolet light and UVLrx technology for both anti-aging and aesthetics purposes. To ensure that Congress attendees are aware of UVLrx Therapeutics’ participation at AMWC, the company has secured inside front cover advertising, as well as a two-page promotional article, in the March/April issue of PRIME Journal, which will be distributed to all Congress attendees as well as the publication’s nearly 100,000 additional print and online subscribers.
“We look forward to sharing our technology with the global aesthetics and anti-aging community at AMWC 2016 and demonstrating, in person, how the UVLrx Treatment System will benefit all physicians practicing in this field,” added UVLrx CSO Ryan Maloney. “We are especially excited that the theme of the Congress this year is prevention, given the clinically proven ability of the wavelengths utilized by the UVLrx Station™ to immediately reduce inflammation caused by such things as pathogens in the bloodstream, stress and a wide range of aesthetic surgical procedures.”
Ultraviolet blood irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion of drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, visit UVLrx.com and stop by the UVLrx Therapeutics booth (F18) at the Congress. Also be sure to attend the lecture “The Must of Detoxification” in Room Auric between 12:00 and 13:00 on Friday, April 1 st, to hear from UVLrx Chief Scientist Ryan Maloney.
The UVLrx Station™ Model UVL1500 is not available for sale in the U.S.
* References to published specific wavelength studies available upon request.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System. For more information, please visit http://uvlrx.com.
About EuroMediCom (organizer of AMWC)
Based in Paris, France, EuroMediCom was co-founded by Catherine Decuyper and Christophe Luino. It is the official organizer of the Aesthetic & Anti-Aging Medicine World Congress (AMWC). This Congress has been launched with a strong belief that effective aging prevention and treatment must be comprehensively addressed integrating two aspects: using aesthetics strategy (dermatology and surgery) for the external appearance, and applying anti-aging medicine for internal well-being. EuroMediCom is not only present in Europe but also partner of many other major congresses in the rest of the world. Since the development of anti-aging medicine, EuroMediCom took an important part in the creation of the first world premier European University Master Program in Preventive, Regenerative and Anti-aging Medicine, recognized today as the best program in the field with an official delivered master degree by the Dresden International University. For more information, please visit http://v1.euromedicom.com/amwc-2016/index.html.
About the World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM)
Based in Paris, France, the World Society of Interdisciplinary Aesthetic and Anti-Aging Medicine (WOSIAM) has quickly become the world’s fastest growing anti-aging medicine society to federate international physicians and scientific societies. The main goal of this nonprofit organization is to promote anti-aging medicine through research and educational events for physicians and the general public. The society is predominantly formed by and for physicians. It is the belief of the society’s board of directors that the best way for anti-aging medicine to advance is by the endorsement of medical doctors competent in administering safe, evidenced-based anti-aging therapeutics. For more information, please visit http://www.wosiam.org.
About the American Academy of Anti-Aging Medicine (A4M)
Based in Boca Raton, Florida, A4M is a leading nonprofit medical society dedicated to the detection, prevention and treatment of age-related diseases. Dedicated to educating physicians, scientists and the public on biomedical sciences, breaking technologies and preventative medicine issues, the A4M is comprised of over 26,000 members from 120 nations worldwide, including healthcare practitioners, scientists, researchers and governmental officials. For more information, see http://www.a4m.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160120006185/en/
Contacts
Press Contact:
Crier Communications
JP Lincoln, President
jp@crierpr.com
310-274-1072 x201
or
Business Contact:
UVLrx Therapeutics
Rowland Hanson, Chairman
Rowland@UVLrx.com